# PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2026-financial-results
Ticker: PYPD
Company: PolyPid
Source: PolyPid
Published: 2026-05-13 11:30 EST
Original Source URL: https://investors.polypid.com
## Summary

Initiated NDA Submission to the FDA for D-PLEX₁₀₀; Completion Expected Imminently  U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the

## Article Body
Initiated NDA Submission to the FDA for D-PLEX₁₀₀; Completion Expected Imminently  U.S. Commercial Partnership Discussions in Late Stages Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the
## Recent Company News
- 2026-06-01 12:30 EST — [PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀](https://biopharmsignal.com/news/PYPD/polypid-completes-new-drug-application-submission-to-fda-for-d-plex) — Source: PolyPid
- 2026-05-20 12:30 EST — [PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference](https://biopharmsignal.com/news/PYPD/polypid-to-participate-in-the-craig-hallum-23rd-annual-institutional-investor-conference) — Source: PolyPid
- 2026-05-13 11:30 EST — [PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PYPD/polypid-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: PolyPid
- 2026-05-06 12:00 EST — [PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026](https://biopharmsignal.com/news/PYPD/polypid-to-report-first-quarter-2026-financial-results-and-operational-highlights-on-may-13-2026) — Source: PolyPid
- 2026-04-28 12:30 EST — [PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting](https://biopharmsignal.com/news/PYPD/polypid-to-present-data-from-shield-ii-phase-3-trial-demonstrating-reduced-severity-of-surgical-site-infection-at-surgical-infection-society-2026-annual-meeting) — Source: PolyPid
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)